The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer.
Hu Z, Liu W, Liu J, Zhou H, Sun C, ChaoTian, Guo X, Zhu C, Shao M, Wang S, Wei L, Liu M, Li S, Wang J, Xu H, Zhu W, Li X, Li J.
Hu Z, et al. Among authors: zhu w.
Antiviral Res. 2024 Nov 11:106035. doi: 10.1016/j.antiviral.2024.106035. Online ahead of print.
Antiviral Res. 2024.
PMID: 39536909